The Daily Papule

Monday 12 October

Clin Exp DermObservational study
Upadacitinib Combined with NB-UVB for Non-Segmental Vitiligo
A Single-Center Prospective Study.
Lu L, Feng J, … senior author Wang TClinical and Experimental Dermatology
Read at publisher(opens in a new tab)
EJD
Journal Club
Brepocitinib in dermatology - from mechanistic rationale to emerging clinical evidence in dermatomyositis and other skin and hair diseases.
Ferreira C, Sánchez BR, … senior author Piqueras PGEuropean Journal of Dermatology
No abstractRead at publisher(opens in a new tab)
Acta DV
Molluscum Contagiosum, Warts and Condylomas during JAK Inhibitor Therapy for Atopic Dermatitis
a Retrospective Series of 17 Cases.
Russo G, Mahé E, … senior author Jachiet MActa Dermato-Venereologica
No abstractRead at publisher(opens in a new tab)

Saturday 10 October

Derm Pract ConceptLetter
Treating Nail Psoriasis with Topical Ruxolitinib in a Patient with Vitiligo.
Ambrogio F, Foti C, … senior author Meduri ARDermatology Practical & Conceptual
No abstractRead at publisher(opens in a new tab)
Derm Pract ConceptLetter
Successful Treatment of Recalcitrant Pyoderma Gangrenosum with Baricitinib in Two Patients with Rheumatoid Arthritis.
Ciolfi C, Raffeiner B, … senior author Piaserico SDermatology Practical & Conceptual
No abstractRead at publisher(opens in a new tab)

Thursday 8 October

Pediatr DermObservational studyCase report
Dupilumab as Add-On Therapy for JAK Inhibitor-Relapsed Pediatric Alopecia Areata: A Case Series.
Fang S, Wang X, … senior author Liu GPediatric Dermatology
Read at publisher(opens in a new tab)

Wednesday 7 October

BJDSystematic review
Secondary Publications From Biologic or Small-molecule Trials in Psoriasis
A Methodological Systematic Review.
Tran HGN, Afach S, … senior author Le Cleach LBritish Journal of Dermatology
No abstractRead at publisher(opens in a new tab)
Derm Ther
Does Baseline Severity of Atopic Dermatitis Impact the Long-Term Efficacy of Abrocitinib? Post-hoc Analysis of Two Randomized Trials.
Pink AE, Rice ZP, … senior author Watkins MDermatology and Therapy
Read at publisher(opens in a new tab)
Acta DVObservational study
Efficacy and Safety of Delgocitinib and Its Impact on Patient's Perspective for Moderate-to-severe Chronic Hand Eczema in Adults
A 16-week Real-world Prospective Multicentre Study.
Pezzolo E, Luyo Saboya RA, … senior author Rossi MActa Dermato-Venereologica
Read at publisher(opens in a new tab)
Derm Ther
Topical Delgocitinib for Capecitabine-Induced Hand-Foot Syndrome: A Therapeutic Option?
Rapparini L, Martelli G, … senior author Starace MDermatology and Therapy
Read at publisher(opens in a new tab)

Tuesday 6 October

Photoderm
Remibrutinib as a Therapeutic Option for Solar Urticaria.
Mijares J, Bhagwat M, … senior author Ramachandran VPhotodermatology, Photoimmunology & Photomedicine
No abstractRead at publisher(opens in a new tab)

Monday 5 October

JID
Targeting the γc pathway in alopecia areata
What does it add in the era of JAK inhibitors?
Kinoshita-Ise M, Ohyama MJournal of Investigative Dermatology
No abstractRead at publisher(opens in a new tab)

Saturday 3 October

JEADVReview
Upcoming novel treatments for hidradenitis suppurativa
An overview of the pipeline.
Tzellos T, Liakou AI, … senior author Prignano FJournal of the European Academy of Dermatology and Venereology
Read at publisher(opens in a new tab)

Friday 2 October

Derm Ther
Baricitinib Efficacy Through 4 Years in Responders and Safety up to 5 Years in Adults with Severe Alopecia Areata
Final Results from BRAVE-AA1 and BRAVE-AA2.
Vleugels RA, Piraccini BM, … senior author King BDermatology and Therapy
Read at publisher(opens in a new tab)
Derm TherObservational study
D-CARE (Delgocitinib-Chronic hAnd Eczema Response Evaluation)
A Retrospective, Multicenter, Real-World Study of Patients with Chronic Hand Eczema (CHE) Treated with Delgocitinib 2% Cream-Temporal Analysis of Symptom and Clinical Sign Response.
Napolitano M, Turco M, … senior author Patruno CDermatology and Therapy
Read at publisher(opens in a new tab)
Derm Ther
Monitoring the Response to JAK Inhibitor Treatment in Alopecia Areata Using Reflectance Confocal Microscopy and Videotrichoscopy
A 60-Week Observational Study.
Kołcz K, Włodyka J, Reich ADermatology and Therapy
Read at publisher(opens in a new tab)
JAADObservational study
Abrocitinib in elderly patients with moderate-to-severe atopic dermatitis
A real-world study of clinical outcomes and appetite changes.
Gan YT, Yan S, … senior author Chen FLJournal of the American Academy of Dermatology
No abstractRead at publisher(opens in a new tab)
Derm TherClinical trial
Efficacy of Apremilast in Patients with Psoriasis with Limited Skin Involvement, Including High-Impact Site Involvement
A Pooled Analysis of Six Trials.
Strober B, Lebwohl M, … senior author Mrowietz UDermatology and Therapy
Read at publisher(opens in a new tab)
Derm Ther
Comparative Pharmacologic Characterization of Povorcitinib (INCB054707) as a Highly Selective Oral JAK1 Inhibitor.
Wass B, Fenix AM, … senior author Macarrón RDermatology and Therapy
Read at publisher(opens in a new tab)

Thursday 1 October

Derm TherObservational study
Long-Term Disease Control During Continuous Treatment with Upadacitinib and Baricitinib for Moderate-to-Severe Atopic Dermatitis
a Real-World Monocentric Retrospective Study.
D'Oria F, Falcidia C, … senior author Gargiulo LDermatology and Therapy
Read at publisher(opens in a new tab)

Journals and topics

JAK inhibitors & other targeted pills

Monday 12 October

Upadacitinib Combined with NB-UVB for Non-Segmental Vitiligo

Journal Club

Molluscum Contagiosum, Warts and Condylomas during JAK Inhibitor Therapy for Atopic Dermatitis

Saturday 10 October

Treating Nail Psoriasis with Topical Ruxolitinib in a Patient with Vitiligo.

Successful Treatment of Recalcitrant Pyoderma Gangrenosum with Baricitinib in Two Patients with Rheumatoid Arthritis.

Thursday 8 October

Dupilumab as Add-On Therapy for JAK Inhibitor-Relapsed Pediatric Alopecia Areata: A Case Series.

Wednesday 7 October

Secondary Publications From Biologic or Small-molecule Trials in Psoriasis

Does Baseline Severity of Atopic Dermatitis Impact the Long-Term Efficacy of Abrocitinib? Post-hoc Analysis of Two Randomized Trials.

Efficacy and Safety of Delgocitinib and Its Impact on Patient's Perspective for Moderate-to-severe Chronic Hand Eczema in Adults

Topical Delgocitinib for Capecitabine-Induced Hand-Foot Syndrome: A Therapeutic Option?

Tuesday 6 October

Remibrutinib as a Therapeutic Option for Solar Urticaria.

Monday 5 October

Targeting the γc pathway in alopecia areata

Saturday 3 October

Upcoming novel treatments for hidradenitis suppurativa

Friday 2 October

Baricitinib Efficacy Through 4 Years in Responders and Safety up to 5 Years in Adults with Severe Alopecia Areata

D-CARE (Delgocitinib-Chronic hAnd Eczema Response Evaluation)

Monitoring the Response to JAK Inhibitor Treatment in Alopecia Areata Using Reflectance Confocal Microscopy and Videotrichoscopy

Abrocitinib in elderly patients with moderate-to-severe atopic dermatitis

Efficacy of Apremilast in Patients with Psoriasis with Limited Skin Involvement, Including High-Impact Site Involvement

Comparative Pharmacologic Characterization of Povorcitinib (INCB054707) as a Highly Selective Oral JAK1 Inhibitor.

Thursday 1 October

Long-Term Disease Control During Continuous Treatment with Upadacitinib and Baricitinib for Moderate-to-Severe Atopic Dermatitis